Stock Research: Daewoong Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Daewoong Pharmaceutical

KOSE:A069620 KR7069620003
26
  • Value
    12
  • Growth
    76
  • Safety
    Safety
    32
  • Combined
    23
  • Sentiment
    45
  • 360° View
    360° View
    26
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Daewoong Pharma manufactures and distributes pharmaceuticals. It operates in the pharmaceutical industry, producing drugs for various treatments. The company distributes its products domestically and internationally. In the last fiscal year, the company had a market cap of $1,374 million, profits of $497 million, and revenue of $963 million. The number of employees is not available.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 26 (better than 26% compared with alternatives), overall professional sentiment and financial characteristics for the stock Daewoong Pharmaceutical are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Daewoong Pharmaceutical. The consolidated Growth Rank has a good rank of 76, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 76% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 32 means that the share price of Daewoong Pharmaceutical is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 68% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 12, which means that the company has a riskier financing structure than 88% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 45, indicating professional investors are more pessimistic about the stock than for 55% of alternative investment opportunities. ...read more

more
Index
KOSPI
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
32 34 40 27
Growth
76 98 43 23
Safety
Safety
12 13 14 8
Sentiment
45 94 67 20
360° View
360° View
26 30 23 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
86 88 93 5
Opinions Change
34 50 50 4
Pro Holdings
n/a 62 38 63
Market Pulse
28 84 61 86
Sentiment
45 94 67 20
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
32 34 40 27
Growth
76 98 43 23
Safety Safety
12 13 14 8
Combined
23 1 12 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
58 44 53 23
Price vs. Earnings (P/E)
65 65 74 52
Price vs. Book (P/B)
25 24 31 24
Dividend Yield
28 27 26 21
Value
32 34 40 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
67 59 52 47
Profit Growth
98 100 87 40
Capital Growth
28 87 40 27
Stock Returns
46 80 13 51
Growth
76 98 43 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
9 30 13 14
Refinancing
16 8 5 19
Liquidity
55 40 41 14
Safety Safety
12 13 14 8

Similar Stocks

Discover high‑ranked alternatives to Daewoong Pharmaceutical and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Korea Investment

KOSE:A071050
Country: South Korea
Industry: Investment Banking & Brokerage
Size: Large
Full Stock Analysis

Kia Motors

KOSE:A000270
Country: South Korea
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Tsumura

TSE:4540
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.